Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration - WSET.com - ABC13

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, Jan. 23, 2014 /PRNewswire/ --

Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration

http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in various drug delivery systems manufacturers and users. Pharmaceutical biotechnical companies and research institutes will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of drug delivery systems and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, new developments and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of drug delivery systems in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are:Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

REPORT HIGHLIGHTS

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach nearly $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.This report provides:• An overview of the global market for drug delivery systems, with a focus on routes of administration.• Analyses of market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.• Discussion of the current state, setbacks, innovations, and the future needs of the market.• Analyses of the regulatory environment and the technology involved, including the latest developments.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY OBJECTIVES 2REASONS FOR DOING THIS STUDY 2INTENDED AUDIENCE 3SCOPE OF THE STUDY 3METHODOLOGY 3INFORMATION SOURCES 3ABOUT THE AUTHOR 3RELATED BCC RESEARCH REPORTS 4BCC RESEARCH ONLINE SERVICES 4DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BYREGION, THROUGH 2018 ($ MILLIONS) 7SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BYREGION, 2011-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 9

NEED FOR THE DOSAGE FORMS 9TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY 11SUSTAINED RELEASE DRUG DELIVERY 11Oral Sustained Release Drug Delivery 11Intramuscular (IM) Injections or Microsyringes 12TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUGDELIVERY 12PRODRUGS 13Subtypes of Prodrugs 14TABLE 3 CLASSIFICATION OF PRODRUGS 14Need for Prodrugs 15TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15IMPLANTS AND INTRAUTERINE DEVICES (IUDS) 16Copper-based Devices 16Hormonal-based Devices 16Mechanism 17TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17TARGETED DRUG DELIVERY 18Delivery Vehicles 18Liposomes 18TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19Micelles and Dendrimers 19Mechanisms of Drug Delivery 19Advantages of Dendrimers 20Biodegradable Particles 20Artificial DNA Nanostructures 20Monoclonal Antibodies 21Applications 21TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22POLYMERIC DRUG DELIVERY 22Applications of Polymers in Drug Delivery 22TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23Pegylation 23TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24Future Perspectives 24CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION 24ORAL DRUG DELIVERY 24TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25INJECTABLE OR PARENTERAL DRUG DELIVERY 25TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25PULMONARY DRUG DELIVERY 26TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26NASAL DRUG DELIVERY 27TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27ORAL MUCOSAL DRUG DELIVERY 27TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUGDELIVERY 28RECTAL DRUG DELIVERY 28TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28OCULAR DRUG DELIVERY 29TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29TRANSDERMAL DRUG DELIVERY 29TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29

CHAPTER 4 REGULATORY ASPECTS 32

NEW PRODUCTS APPROVED IN 2009-2013 32TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32FDA RECALLS AND SAFETY ALERTS 35TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37

CHAPTER 5 NEW DEVELOPMENTS 40

NEW PARTNERSHIPS, MERGERS AND ACQUISITION 40TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41NEW PRODUCTS 42TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43PIPELINE PRODUCTS 44TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44

CHAPTER 6 GLOBAL MARKETS 47

MARKET BY TYPE 47MARKET OVERVIEW 47MARKET REVENUE 50TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH2018 ($ MILLIONS) 50FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($MILLIONS) 50MARKET SHARE 51TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 52MARKET BY REGION 52SUSTAINED RELEASE DRUG DELIVERY SYSTEM 52Market Overview 53Market Revenue 54TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 54FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 54Market Share 55TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,FOR 2012 (%) 55FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,FOR 2012 (%) 55PRODRUGS 55Market Overview 56Market Revenue 56TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 56FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 56Market Share 57TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 57FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 57IMPLANTS AND IUDS 58Market Overview 58Market Revenue 58TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018($ MILLIONS) 59FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($MILLIONS) 59Market Share 59TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60TRANSMUCOSAL DELIVERY SYSTEMS 60Market Overview 61Market Revenue 63TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 63FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 63Market Share 64TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012(%) 64FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012(%) 64TARGETED DRUG DELIVERY 64Market Overview 65Market Revenue 66TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH2018 ($ MILLIONS) 66FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 66Market Share 67TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67TRANSDERMAL DRUG DELIVERY SYSTEM 67Market Overview 68Market Revenue 68TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 68FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 69Market Share 69TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,2012 ($ MILLIONS) 69FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BYREGION, 2012 (%) 69POLYMERIC DRUG DELIVERY 70Market Overview 70Market Revenue 71TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 71FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 71Market Share 72TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72MARKET BY END USERS 72MARKET OVERVIEW 73MARKET REVENUE 77TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, THROUGH 2018 ($ MILLIONS) 78FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, 2011-2018 ($ MILLIONS) 78MARKET SHARE 79TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,2012 (%) 80FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,2012 (%) 80

CHAPTER 7 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION 82

TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTEOF ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 83FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTEOF ADMINISTRATION, 2011-2018 ($ MILLIONS) 83MARKET BY TYPE 84ORAL, TOPICAL AND INJECTABLE DRUG DELIVERIES 84Market Overview 85Market Revenue 86TABLE 43 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERYBY TYPE, THROUGH 2018 ($ MILLIONS) 86FIGURE 20 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERYBY TYPE, 2011-2018 ($ MILLIONS) 87TRANSMUCOSAL DELIVERY SYSTEMS 87Market Overview 88Market Revenue 90TABLE 44 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,THROUGH 2018 ($ MILLIONS) 91FIGURE 21 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,2011-2018 ($ MILLIONS) 91TRANSDERMAL DRUG DELIVERY SYSTEM 92Market Overview 93Market Revenue 93TABLE 45 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,THROUGH 2018 ($ MILLIONS) 93FIGURE 22 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,2011-2018 ($ MILLIONS) 93MARKET BY REGION 94MARKET OVERVIEW 94MARKET REVENUE 95Oral, Topical, Injectables 96TABLE 46 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERYBY REGION, THROUGH 2018 ($ MILLIONS) 96FIGURE 23 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERYBY REGION, 2011–2018 ($ MILLIONS) 96Transmucosal Drug Delivery 97TABLE 47 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 97FIGURE 24 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 97Transdermal Drug Delivery 98TABLE 48 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 98FIGURE 25 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 98INDUSTRY STRUCTURE 99ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY 99Market Leaders 99TABLE 49 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUGDELIVERY, 2012 99Market Share of Oral Drug Delivery 100TABLE 50 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012(%) 101FIGURE 26 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012(%) 101Market Share of Injectable Drug Delivery 101TABLE 51 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,2012 (%) 102FIGURE 27 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,2012 (%) 102Market Share of Topical Drug Delivery 102TABLE 52 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,2012 (%) 103FIGURE 28 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,2012 (%) 103TRANSMUCOSAL DRUG DELIVERY 104Market Leaders 104TABLE 53 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY 104Market Share of Nasal Drug Delivery 105TABLE 54 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASALDRUG DELIVERY, 2012 (%) 105FIGURE 29 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASALDRUG DELIVERY, 2012 (%) 106Market Share of Oral Mucosal/Buccal Drug Delivery 106TABLE 55 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,2012 (%) 106FIGURE 30 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,2012 (%) 106Market Share of Rectal Drug Delivery 107TABLE 56 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,2012 (%) 107FIGURE 31 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,2012 (%) 107Market Share of Ocular Drug Delivery 108TABLE 57 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,2012 (%) 108FIGURE 32 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,2012 (%) 108Market Share of Vaginal Drug Delivery 109TABLE 58 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,2012 (%) 109FIGURE 33 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,2012 (%) 110TRANSDERMAL DRUG DELIVERY 110Market Leaders 110TABLE 59 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 110Market Share 111TABLE 60 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUGDELIVERY, 2012 (%) 111FIGURE 34 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUGDELIVERY, 2012 (%) 111

CHAPTER 8 PATENT ANALYSIS 113

PATENTS BY YEAR 113TABLE 61 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009–JULY 2013 113FIGURE 35 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 113PATENTS BY CATEGORY 114TABLE 62 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 114FIGURE 36 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 115PATENTS BY TYPE 115TABLE 63 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 115PATENTS BY COMPANY 116TABLE 64 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 116PATENTS BY COUNTRY 118TABLE 65 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 118PATENTS BY ASSIGNEE 119TABLE 66 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 119FIGURE 37 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 119

CHAPTER 9 CURRENT SITUATION 121

CHAPTER 10 COMPANY PROFILES 125

3M COMPANY 125

ABBOTT LABORATORIES 125

ACTAVIS INC. 126

AKELA PHARMA INC. 126

AKORN, INC. 127

ALCON INC. 127

ALEXION PHARMACEUTICALS, INC. 128

ALKERMES 128

ALLERGAN INC. 128

AMGEN INC. 129

A.P. PHARMA 130

APTALIS PHARMA INC. 130

ASTELLAS PHARMA INC. 131

ASTRAZENECA PLC 131

ATON PHARMA 132

BAUSCH & LOMB 132

BAXTER INTERNATIONAL INC. 132

BAYER HEALTHCARE PHARMACEUTICALS 133

BIOGEN IDEC 133

BIOSANTE PHARMACEUTICALS, INC. 134

BOEHRINGER INGELHEIM 134

BOSTON SCIENTIFIC 135

BRISTOL MYERS SQUIBB 135

CELGENE CORPORATION 136

CEPHALON, INC. 136

COLUMBIA LABORATORIES, INC. 137

EISAI CO., LTD 137

ELAN DRUG TECHNOLOGIES 138

ENZON PHARMACEUTICALS 138

GENENTECH INC. 139

GENEREX BIOTECHNOLOGY CORPORATION 139

GENZYME CORPORATION 140

GILEAD SCIENCES, INC. 141

GLAXOSMITHKLINE PLC 141

HISAMITSU PHARMACEUTICAL CO., INC. 142

IMCLONE SYSTEMS INC. 142

JANSSEN BIOTECH, INC. 143

JOHNSON & JOHNSON 143

KEMPHARM, INC. 144

K.V. PHARMACEUTICAL CO. 144

LAVIPHARM CORPORATION 145

MANNKIND CORPORATION 145

MERCK & CO. 146

MYLAN LABORATORIES INC. 146

NEKTAR THERAPEUTICS 147

NEUROGESX INC. 147

NEWGEN BIOPHARMA 148

NOVARTIS AG 148

NOVAVAX, INC. 149

NOVEN PHARMACEUTICALS, INC. 149

NYCOMED US INC. 150

OSI PHARMACEUTICALS, INC. 150

PAR PHARMACEUTICAL COMPANIES, INC. 151

PDL BIOPHARMA, INC. 151

PFIZER INC. 152

QLT INC. 152

ROCHE HOLDING AG 153

SANOFI SA 153

TEVA PHARMACEUTICAL INDUSTRIES LTD. 154

THERAJECT, INC. 155

UMEWORLD LTD. 155

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 156

XEL PHARMACEUTICALS, INC. 156

CHAPTER 11 APPENDIX I 158LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY

REGION, THROUGH 2018 ($ MILLIONS) 7

TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10

TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG

DELIVERY 12

TABLE 3 CLASSIFICATION OF PRODRUGS 14

TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15

TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17

TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19

TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22

TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23

TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24

TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25

TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25

TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26

TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27

TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY 28

TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28

TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29

TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29

TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32

TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35

TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37

TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41

TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43

TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44

TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018

($ MILLIONS) 50

TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51

TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 54

TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

FOR 2012 (%) 55

TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 56

TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 57

TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($

MILLIONS) 59

TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60

TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 63

TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%) 64

TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 66

TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67

TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 68

TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,

2012 ($ MILLIONS) 69

TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 71

TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72

TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

THROUGH 2018 ($ MILLIONS) 78

TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

2012 (%) 80

TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF

ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 83

TABLE 43 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY

BY TYPE, THROUGH 2018 ($ MILLIONS) 86

TABLE 44 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,

THROUGH 2018 ($ MILLIONS) 91

TABLE 45 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,

THROUGH 2018 ($ MILLIONS) 93

TABLE 46 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY

BY REGION, THROUGH 2018 ($ MILLIONS) 96

TABLE 47 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 97

TABLE 48 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 98

TABLE 49 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG

DELIVERY, 2012 99

TABLE 50 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012

(%) 101

TABLE 51 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,

2012 (%) 102

TABLE 52 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,

2012 (%) 103

TABLE 53 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY 104

TABLE 54 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL

DRUG DELIVERY, 2012 (%) 105

TABLE 55 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,

2012 (%) 106

TABLE 56 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,

2012 (%) 107

TABLE 57 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,

2012 (%) 108

TABLE 58 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,

2012 (%) 109

TABLE 59 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 110

TABLE 60 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG

DELIVERY, 2012 (%) 111

TABLE 61 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009–JULY 2013 113

TABLE 62 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 114

TABLE 63 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 115

TABLE 64 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 116

TABLE 65 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 118

TABLE 66 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 119

LIST OF FIGURES

SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY

REGION, 2011-2018 ($ MILLIONS) 7

FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($

MILLIONS) 50

FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 52

FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 54

FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR

2012 (%) 55

FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018

($ MILLIONS) 56

FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 57

FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($

MILLIONS) 59

FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60

FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 63

FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012

(%) 64

FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 66

FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67

FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 69

FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 69

FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 71

FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72

FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY

APPLICATIONS, 2011-2018 ($ MILLIONS) 78

FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

2012 (%) 80

FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE

OF ADMINISTRATION, 2011-2018 ($ MILLIONS) 83

FIGURE 20 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY

BY TYPE, 2011-2018 ($ MILLIONS) 87

FIGURE 21 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,

2011-2018 ($ MILLIONS) 91

FIGURE 22 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,

2011-2018 ($ MILLIONS) 93

FIGURE 23 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY

BY REGION, 2011–2018 ($ MILLIONS) 96

FIGURE 24 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 97

FIGURE 25 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 98

FIGURE 26 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012

(%) 101

FIGURE 27 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,

2012 (%) 102

FIGURE 28 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,

2012 (%) 103

FIGURE 29 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL

DRUG DELIVERY, 2012 (%) 106

FIGURE 30 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,

2012 (%) 106

FIGURE 31 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,

2012 (%) 107

FIGURE 32 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,

2012 (%) 108

FIGURE 33 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,

2012 (%) 110

FIGURE 34 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG

DELIVERY, 2012 (%) 111

FIGURE 35 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 113

FIGURE 36 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 115

FIGURE 37 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 119

To order this report: Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WSET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.